How many insider trades does FilingIQ track for ALNY?

FilingIQ tracks 1,699 Form 4 insider transactions for ALNY (ALNYLAM PHARMACEUTICALS, INC.), covering filings from Jan 22, 2015 onwards. 150 of those were filed in the last 90 days.

Are ALNY insiders net buyers or net sellers?

Across the full Form 4 history for ALNY, 11 transactions (1%) were open-market purchases and 1,125 (66%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ALNY insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ALNY in?

ALNYLAM PHARMACEUTICALS, INC. (ALNY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $44.11B.

ALNY insider trading

Healthcare

ALNYLAM PHARMACEUTICALS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

1,699

Last 90 days

150

Buys / sells

1% / 66%

Market cap

$44.11B

About ALNYLAM PHARMACEUTICALS, INC.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Company website: www.alnylam.com

ALNY insider activity at a glance

FilingIQ has scored 1,699 insider transactions for ALNY since Jan 22, 2015. The most recent filing in our index is dated May 13, 2026.

Across the full history, 11 open-market purchases and 1,125 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ALNY insider trades is 58.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ALNY trades on FilingIQ Raw filings on SEC EDGAR

Latest ALNY Form 4 filings

Vaishnaw Akshay President

S Aug 4, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding ALNY

Casdin Capital, LLC

$41.31M · 3.2% of AUM

Ikarian Capital, LLC

$20.43M · 2.2% of AUM

Politicians who have traded ALNY

Hanna, Richard L.

U.S. Rep. , NY · 208 trades

Comstock, Barbara J Honorable

U.S. Rep. , VA · 78 trades

Frequently asked

How many insider trades does FilingIQ track for ALNY?: FilingIQ tracks 1,699 Form 4 insider transactions for ALNY (ALNYLAM PHARMACEUTICALS, INC.), covering filings from Jan 22, 2015 onwards. 150 of those were filed in the last 90 days.
Are ALNY insiders net buyers or net sellers?: Across the full Form 4 history for ALNY, 11 transactions (1%) were open-market purchases and 1,125 (66%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ALNY insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ALNY in?: ALNYLAM PHARMACEUTICALS, INC. (ALNY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $44.11B.

Methodology & sources

Every ALNY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.